Laurence Albiges
劳伦斯·阿尔比热斯
MD, PhD
Head, Department of Medical Oncology for Genitourinary Tumors泌尿系肿瘤内科主任
👥Biography 个人简介
Laurence Albiges, MD PhD is Head of the Department of Medical Oncology for Genitourinary Tumors at Institut Gustave Roussy. She is a world-renowned expert in renal cell carcinoma biology and systemic therapy, best known for the CABOSUN trial that established cabozantinib's superiority over sunitinib in intermediate/poor-risk advanced RCC. She chairs the ESMO RCC guidelines committee and has made pivotal contributions to non-clear cell RCC management.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
CABOSUN Trial: Cabozantinib in Intermediate/Poor-Risk RCC
Led CABOSUN, the randomized phase II trial demonstrating superior PFS and ORR for cabozantinib over sunitinib in intermediate/poor-risk treatment-naive advanced RCC, supporting FDA approval and establishing cabozantinib as a preferred option in higher-risk patients.
Non-Clear Cell RCC Systemic Therapy
Conducted pivotal clinical and translational studies characterizing treatment outcomes in papillary, chromophobe, and collecting duct RCC subtypes, generating evidence that informed subtype-specific treatment recommendations and trial designs.
RCC Tumor Biology and Genomic Landscape
Led molecular characterization studies of clear cell and non-clear cell RCC tumors, identifying genomic drivers including PBRM1, BAP1, and MET alterations that predict prognosis and differential sensitivity to targeted and immunotherapy agents.
Representative Works 代表性著作
Cabozantinib versus Sunitinib as Initial Targeted Therapy for Patients with Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk
Journal of Clinical Oncology (2017)
CABOSUN randomized phase II trial showing superior PFS and ORR for cabozantinib versus sunitinib in intermediate/poor-risk advanced RCC, leading to FDA approval and changes in first-line treatment selection.
ESMO Clinical Practice Guidelines: Renal Cell Carcinoma — 2022 Update
Annals of Oncology (2022)
Comprehensive guideline update covering IO+TKI and dual IO combinations, cabozantinib, and non-clear cell RCC management, serving as the primary European reference for advanced kidney cancer treatment.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Brian I. Rini
Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
Robert J. Motzer
Memorial Sloan Kettering Cancer Center
Toni K. Choueiri
Dana-Farber Cancer Institute, Harvard Medical School
Sumanta Pal
City of Hope Comprehensive Cancer Center
关注 劳伦斯·阿尔比热斯 的研究动态
Follow Laurence Albiges's research updates
留下邮箱，当我们发布与 Laurence Albiges（Institut Gustave Roussy）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment